Immunotherapy for Renal-Cell Carcinoma Saves Lives Immunotherapy for Renal-Cell Carcinoma Saves Lives
A 5-year randomised, placebo-controlled trial of pembrolizumab found a 38% reduction in death vs placebo.Medscape News UK
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology Clinical Summary Source Type: news
More News: Cancer & Oncology | Carcinoma | Health | Hematology | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma